Alkem Laboratories announced a strong performance in Q2 FY26, with revenue increasing by 17.2% to ₹40,010 Mn. The company’s EBITDA grew by 22.3% to ₹9,208 Mn, resulting in a margin of 23.0%. Domestic sales increased by 12.4%, while international sales saw a significant rise of 29.5%. Alkem’s strategic focus on key markets and new product launches drove the positive results.
Financial Performance Highlights
Alkem Laboratories reported robust financial results for the second quarter of fiscal year 2026. Key highlights include:
- Total Revenue from Operations: Increased by 17.2% year-over-year to ₹40,010 Mn.
- EBITDA: Grew by 22.3% year-over-year to ₹9,208 Mn, with an improved margin of 23.0%.
- PAT: Reached ₹7,651 Mn, a 11.1% increase compared to the previous year, resulting in a margin of 19.1%.
Segment Performance
The company experienced growth across both domestic and international markets:
- Domestic Business: Revenue reached ₹27,660 Mn, reflecting a 12.4% year-over-year growth.
- International Business: Sales totaled ₹11,890 Mn, demonstrating a substantial 29.5% year-over-year increase. US sales grew by 28.0% to ₹7,649 Mn.
Key Business Updates
Several factors contributed to Alkem’s strong performance in Q2 FY26:
- Alkem became the number one company in the Acute segment within the Indian Pharmaceutical Market (IPM).
- The company’s growth in the Indian market aligned with the IPM’s overall growth of 6.4%.
- Alkem outperformed the market in six key therapy areas.
Investments and Approvals
Alkem continues to invest in research and development and expand its product offerings:
- R&D expenses for the quarter amounted to ₹1,302 Mn, representing 3.3% of total revenue.
- The company filed 2 ANDAs, received 1 ANDA tentative approval, and launched 4 products in the US market during the quarter. As of September 30, 2025, Alkem has 187 ANDAs filed with the USFDA.
Source: BSE
